drugset / Trial / NCT03791476

RUCONEST® as a Therapeutic Strategy to Reduce the Incidence of Delayed Graft Function

NCT03791476 ↗

RandomizedParallel-groupTriple-blindTreatment

Summary

An unmet medical need exists for therapeutic regimens in transplantation that allow immediate postoperative graft function, thereby improving graft survival. Delayed graft function (DGF) after transplantation is the most common complication affecting kidney allographs in the immediate transplant period. The specific aim of this study is to evaluate the effect of recombinant human C1-inhibitor (rhC1INH), as a kidney recipient intra- and post operative treatment strategy to decrease systemic inflammation and decrease the incidence of DGF from donation after cardiac death donors (DCD).

Timeline

Start
2019-06-21
Primary completion
2022-01
Completion
2022-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject rhC1INH Protein / enzyme biologic 50 iu/kg Intravenous

Indications